Kenvue Inc.

Kenvue reported Q2 2026 net sales of $3.96 billion, up from $3.84 billion in Q2 2025, with diluted EPS increasing to $0.24 from $0.22. Year-to-date net income rose to $930 million from $742 million. The company also provided an update on its pending merger with Kimberly-Clark, confirming shareholder approval from both companies and the expiration of the HSR waiting period, with the transaction still awaiting foreign regulatory approvals.

Kenvue Inc. reported strong second-quarter 2026 financial results, with net sales increasing 3.0% to $3.96 billion and diluted EPS rising 9% to $0.24. The company achieved its third consecutive quarter of net and organic sales growth, with broad-based gains across all segments and regions. Kenvue also announced FDA approval for Tylenol with Naproxen and confirmed that its acquisition by Kimberly-Clark is expected to close in the fourth quarter of 2026.

Kenvue Inc. reported strong financial results for the first fiscal quarter of 2026, with significant increases in net income, diluted EPS, net sales, and operating income. The company also provided an update on its pending merger with Kimberly-Clark Corporation, confirming shareholder approvals and the expiration of the Hart-Scott-Rodino waiting period, with foreign regulatory approvals still pending. Cash flows from operating activities also saw a healthy increase.

Kenvue Inc. reported strong financial results for the fiscal first quarter ended March 29, 2026, with net sales increasing 4.5% to $3.909 billion and diluted earnings per share rising 47% to $0.25. The company achieved organic sales growth for the second consecutive quarter, alongside significant year-over-year improvements in gross margin, operating margin, and EPS. Kenvue is also progressing with its pending merger with Kimberly-Clark, anticipated to close in the second half of 2026, and has initiated a 2026 Restructuring Initiative to optimize its operating model.

Kenvue Inc. announced that its current Chief Financial Officer, Amit Banati, will step down from his role effective May 12, 2026. The company has appointed Heather Howlett, currently the Chief Accounting Officer, as interim Chief Financial Officer and Chief Accounting Officer, effective the same date. Ms. Howlett will also serve as the principal financial and accounting officer during her interim term. She will receive a monthly stipend of $125,000 in addition to her existing compensation.